January 9, 2020 / 12:19 PM / 7 months ago

Amag Pharmaceuticals to divest two women's health drugs, CEO to step down

Jan 9 (Reuters) - Amag Pharmaceuticals Inc said on Thursday it would divest two of its women's health drugs, after the drugmaker conducted a strategic review under pressure from hedge fund Caligan Partners.

The company also said Chief Executive Officer William Heiden would step down.

It said it would divest Vyleesi, a female libido drug, and Intrarosa, a treatment for pain in post-menopausal women, as it had received preliminary expressions of interest in buying and sub-licensing the rights to the drugs. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below